# Amyl Therapeutics SRL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amyl-therapeutics

- Industry: Biotechnology
- Headquarters: Liege, Belgium
- Website: www.amyltx.com
- Total disclosed funding: $14M
- Latest round: Series A (Sep 1, 2026)
- Investors on record: 7

## About

Based in Liege, Belgium and founded in 2020, Amyl Therapeutics SRL operates as a biotechnology company that develops novel therapies that helps treat patients with amyloidosis diseases. The company was co-founded by Pierre Vandepapeliere (CEO & CMO) and Florent Gros. In September 2026, Amyl Therapeutics raised EUR 3.85 million in series A funding from Noshaq and Merieux Equity Partners. The round was part of larger EUR 8.25 million Series A and venture debt funding. The round was part of larger EUR 22.95 million series A extension funding.

Amyl Therapeutics provides a technology platform named ClariTY that focuses on treating rare and severe protein misfolding diseases. The company also uses a novel mechanism that focuses on antibody light chain (AL) or transthyretin (TTR).

The company plans to utilize the September 2026 funding to advance its lead candidate through GMP preparation, preclinical studies, clinical testing readiness, and research expansion.

## Funding rounds

- Series A, Sep 1, 2026, $4.5M — Merieux Equity Partners, Noshaq
- Series A, Nov 2, 2023, $5.4M — Merieux Equity Partners, Noshaq
- Series A, Apr 9, 2021, $4.3M — Smedvig Capital, Merieux Equity Partners, Sambrinvest, Noshaq, Ifoghas Investments, 6K Venture Capital, JFG Life Sciences Foundation

## Investors

- Smedvig Capital (https://capitalatlas.ai/funds/smedvig-capital) — Series A
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series A
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series A
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A
- Ifoghas Investments — Series A
- 6K Venture Capital — Series A
- JFG Life Sciences Foundation — Series A